Kennedy Capital Management, Inc. Spectrum Pharmaceuticals Inc Transaction History

Kennedy Capital Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.65 - $1.31 $3.17 Million - $6.39 Million	4,881,037 New	4,881,037 $4.69 Million
Q4 2019 Feb 14, 2020	SELL	$3.5 - $10.35 $427,528 - $1.26 Million	-122,151 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$7.03 - $9.7 $24,373 - $33,629	-3,467 Reduced 2.76%	122,151 $1.01 Million
Q2 2019 Aug 14, 2019	SELL	$7.36 - $11.26 $10,046 - $15,369	-1,365 Reduced 1.07%	125,618 $1.08 Million
Q1 2019 May 13, 2019	BUY	$9.08 - $11.84 $271,927 - $354,584	29,948 Added 30.86%	126,983 $1.36 Million
Q4 2018 Feb 12, 2019	SELL	$6.39 - $16.99 $1,348 - $3,584	-211 Reduced 0.22%	97,035 $849,000
Q3 2018 Nov 14, 2018	SELL	$16.52 - $24.82 $3.72 Million - $5.58 Million	-224,998 Reduced 69.82%	97,246 $1.63 Million
Q2 2018 Aug 14, 2018	BUY	$14.31 - $21.75 $1.29 Million - $1.96 Million	90,217 Added 38.88%	322,244 $6.75 Million
Q1 2018 May 14, 2018	BUY	$16.09 - $23.07 $1.3 Million - $1.87 Million	81,035 Added 53.67%	232,027 $3.73 Million
Q4 2017 Feb 13, 2018	SELL	$13.36 - $20.73 $4.87 Million - $7.55 Million	-364,427 Reduced 70.7%	150,992 $2.86 Million
Q3 2017 Nov 13, 2017	BUY	$8.75 - $14.07 $4.51 Million - $7.25 Million	515,419	515,419 $7.25 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.